Messeih A A, Lipton A, Santen R J, Harvey H A, Boucher A E, Murray R, Ragaz J, Buzdar A U, Nagel G A, Henderson I C
Cancer Treat Rep. 1985 Sep;69(9):1003-4.
Marked leukopenia and/or thrombocytopenia occurred in 12 of 1333 patients treated with aminoglutethimide (0.9% incidence). Depression of blood cell counts was evident within 7 weeks of starting treatment. No delayed toxicity was encountered. Blood cell counts recovered promptly upon cessation of aminoglutethimide in all but one patient, who died from septicemia and marrow aplasia.
在接受氨鲁米特治疗的1333例患者中，有12例出现明显的白细胞减少和/或血小板减少（发生率为0.9%）。血细胞计数在开始治疗后7周内明显下降。未发现迟发性毒性。除1例死于败血症和骨髓再生障碍的患者外，所有患者在停用氨鲁米特后血细胞计数迅速恢复。
